Earnings Call Summary | Biofrontera(BFRI.US) Q1 2024 Earnings Conference
Earnings Call Summary | Biofrontera(BFRI.US) Q1 2024 Earnings Conference
The following is a summary of the Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript:
以下是Biofrontera Inc.（BFRI）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Biofrontera reported a decrease in Q1 2024 revenues to $7.9 million, impacted by the Change Healthcare data breach.
Operating expenses were $13.4 million, showing a reduction from the prior year's figure.
Net loss of $10.4 million was notably impacted by the accounting for B-3 convertible preferred warrants.
Biofrontera報告稱，受Change Healthcare數據泄露的影響，2024年第一季度收入下降至790萬美元。
運營支出爲1,340萬美元，比上年的數字有所減少。
淨虧損1,040萬美元受到B-3可轉換優先權證會計的顯著影響。
Business Progress:
業務進展：
The renegotiated license and supply agreement for Ameluz resulted in cost reductions.
They secured a total of $16 million funds in 2024 to support growth and expansion.
Despite a temporary slump due to a cyberattack, the company reported growth in revenues year-to-date as of April 30th, 2024.
There was a surge in demand for BF-RhodoLED lamps, indicating a positive future growth trajectory.
Keeping cost management in perspective, Biofrontera is set to take over the clinical trials departments, granting them a direct oversight of the trial efficacy.
重新談判的Ameluz許可和供應協議降低了成本。
他們在2024年共獲得了1600萬美元的資金，以支持增長和擴張。
儘管由於網絡攻擊而暫時下滑，但該公司報告稱，截至2024年4月30日，年初至今的收入有所增長。
對BF-Rhodoled燈的需求激增，表明未來的增長軌跡良好。
從成本管理的角度來看，Biofrontera將接管臨床試驗部門，允許他們直接監督試驗的有效性。
More details: Biofrontera IR
更多詳情： Biofrontera IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。